Additional Results

Safety Observations

One participant in Cohort 1 received a partial dose of efanesoctocog alfa during the first infusion on Day 1 due to a treatment-emergent adverse event of palpitation. A concurrent event of anxiety was also reported. The event of palpitation was assessed by the investigator as nonserious, mild in severity, and not related to study drug. The participant received full doses of efanesoctocog alfa for the next 3 infusions and the event of palpitation did not recur. This participant was excluded from the pharmacokinetic analysis set.

Supplementary Table. Calculated Pharmacokinetic Parameters Derived From the Two-Stage Chromogenic Assay*,†

	Cohort 1 50 IU/kg efanesoctocog alfa (n=9)		Cohort 2 65 IU/kg efanesoctocog alfa (n=14)	
	Day 1‡ (n=9)	Day 22 (n=9)	Day 1‡ (n=14)	Day 22 (n=14)
$t_{1/2}$, h	–	43.9 (40.1–48.0)	–	42.5 (39.9–45.3)
C_{max},§ IU/dL	108 (97–120)	115 (104–126)	155 (141–171)	172 (159–186)
$AUC_{0–tau}$, h × IU/dL	5630 (4950–6400)	5860 (5350–6420)	7100 (6360–7920)	7870 (7030–8820)
CL_{SS}, mL/h/kg	–	0.85 (0.778–0.934)	–	0.83 (0.737–0.925)
IR, IU/dL per IU/kg	2.16 (1.93–2.41)	2.15 (1.94–2.39)	2.39 (2.17–2.63)	2.52 (2.33–2.73)
MRT_{inf}, h	–	60.8 (54.2–68.2)	–	54.3 (51.5–57.2)
Accumulation index¶	–	1.08 (1.06–1.10)	–	1.07 (1.06–1.09)

$AUC_{0–tau}$, area under the activity-time curve from hour 0 over the dosing interval; CL_{ss}, clearance at steady state; C_{max}, maximum FVIII activity; FVIII, factor VIII; IR, incremental recovery; MRT, mean residence time; $t_{1/2}$, elimination half-life.

*Values are geometric mean (95% confidence interval).

[†]BIOPHEN™ Factor VIII:C assay (Hyphen BioMed) using a product-specific standard.

[‡]Some parameters were not calculated for the first dose administered because they were more accurately calculated after the final dose when blood sampling could continue for 14 days post dose.

[§]Day 22 value is C_{max} at steady state.

[¶]Accumulation index was defined as the ratio of $AUC_{0\text{-}tau}$ at steady state over $AUC_{0\text{-}tau}$ after the first dose.